Ablynx Stock

Stocks

16/10/18	AstraZeneca : Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit	RE
27/04/18	Sanofi : sees new acquisitions and drugs reviving growth	RE
17/04/18	Blackstone LP : Sanofi in talks to sell generics arm to Advent for 1.9 billion euros	RE
29/03/18	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
29/03/18	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
29/03/18	Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	RE
23/03/18	Ablynx : Drugmaker Novo Nordisk looks to former oil boss to energise M&A	RE
07/02/18	Ablynx : Sanofi's return to profit growth this year slower than hoped	RE
30/01/18	Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom	RE
30/01/18	Ablynx : Chipmakers, Sanofi deal dominate European share trading	RE
30/01/18	Ablynx : Novo Nordisk remains on hunt for biopharma deals	RE
23/01/18	Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion	RE
23/01/18	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE

20/11/20	Immunicum : and DCprime Combine Forces to Establish Leader in Cell-Based Cancer Immunotherapies	AQ
19/06/18	Ablynx : SANOFI COMPLETES ITS ACQUITISION OF ABLYNX FOLLOWING THE EXPIRATION OF THE SQUEEZE-OUT PROCEDURE	GL
28/05/18	Ablynx : PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")	GL
28/05/18	Ablynx : PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")	GL
26/05/18	Ablynx : NOTICE IN RELATION TO THE CONVERTIBLE BONDS DUE MAY 2020	GL

19/06/18	SANOFI : a finalisé l'acquisition d'Ablynx
15/05/18	Les marchés européens marquent une pause, scrutent la politique italienne
14/05/18	Sanofi : A suivre aujourd'hui
14/05/18	SANOFI : détient 95,60% des actions d'ABLYNX
27/04/18	Sanofi : Les taux de change freinent les résultats, T2 terne en vue

Manager	Title	Age	Since
Geert Deschamps CEO	Chief Executive Officer	-	07/03/2025

Director	Title	Age	Since
Kristine de Sutter BRD	Director/Board Member	-	01/04/2019
Pieter Oldenziel BRD	Director/Board Member	-	01/01/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABLYNX	-.--%	+0.09%	-	-	0
WUXI APPTEC CO., LTD.	+2.41%	+0.29%	+39.41%	+73.38%	64.69B
ARGENX SE	-0.15%	+7.50%	+11.42%	+75.22%	54.78B
LONZA GROUP AG	+0.57%	+4.60%	+7.71%	+100.57%	53.49B
IQVIA HOLDINGS INC.	+0.37%	+4.67%	+26.68%	+54.16%	45.98B
BEONE MEDICINES AG	-1.21%	+2.32%	+21.50%	+126.83%	42.94B
REVOLUTION MEDICINES, INC.	-0.37%	+5.07%	+243.23%	+834.48%	40.08B
CELLTRION, INC.	+0.05%	+0.21%	+18.06%	+48.50%	33.52B
WUXI BIOLOGICS (CAYMAN) INC.	-0.04%	-8.57%	+22.75%	+2.83%	23.97B
GENMAB A/S	-0.38%	+5.68%	+38.39%	+29.86%	23.67B
Average	+0.12%	+2.41%	+47.68%	+149.54%	42.57B
Weighted average by Cap.	+0.31%	+2.73%	+45.80%	+151.47%